Citadel Advisors’s Akero Therapeutics AKRO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-685,842
| Closed | -$32.6M | – | 12552 |
|
|
2025
Q3 | $32.6M | Sell |
685,842
-483,840
| -41% | -$23.4M | 0.01% | 1788 |
|
|
2025
Q2 | $62.4M | Sell |
1,169,682
-739,648
| -39% | -$33.6M | 0.01% | 1071 |
|
|
2025
Q1 | $77.3M | Buy |
1,909,330
+554,437
| +41% | +$23.5M | 0.01% | 847 |
|
|
2024
Q4 | $37.7M | Buy |
1,354,893
+1,204,992
| +804% | +$36.5M | 0.01% | 1528 |
|
|
2024
Q3 | $4.3M | Sell |
149,901
-245,216
| -62% | -$6.39M | ﹤0.01% | 4193 |
|
|
2024
Q2 | $9.27M | Sell |
395,117
-24,543
| -6% | -$525K | ﹤0.01% | 2860 |
|
|
2024
Q1 | $10.6M | Sell |
419,660
-65,365
| -13% | -$1.57M | ﹤0.01% | 2880 |
|
|
2023
Q4 | $11.3M | Buy |
485,025
+182,438
| +60% | +$3.6M | ﹤0.01% | 2676 |
|
|
2023
Q3 | $15.3M | Sell |
302,587
-23,305
| -7% | -$1.09M | ﹤0.01% | 2168 |
|
|
2023
Q2 | $15.2M | Sell |
325,892
-529,816
| -62% | -$24.3M | ﹤0.01% | 2161 |
|
|
2023
Q1 | $32.7M | Buy |
855,708
+593,991
| +227% | +$26.5M | 0.01% | 1452 |
|
|
2022
Q4 | $14.3M | Buy |
261,717
+84,556
| +48% | +$3.62M | ﹤0.01% | 2353 |
|
|
2022
Q3 | $6.03M | Buy |
177,161
+78,551
| +80% | +$1.2M | ﹤0.01% | 3555 |
|
|
2022
Q2 | $932K | Buy |
98,610
+10,800
| +12% | +$113K | ﹤0.01% | 7185 |
|
|
2022
Q1 | $1.25M | Buy |
87,810
+60,371
| +220% | +$1.06M | ﹤0.01% | 7203 |
|
|
2021
Q4 | $580K | Sell |
27,439
-5,430
| -17% | -$120K | ﹤0.01% | 9328 |
|
|
2021
Q3 | $735K | Sell |
32,869
-25,193
| -43% | -$570K | ﹤0.01% | 8931 |
|
|
2021
Q2 | $1.44M | Sell |
58,062
-82,813
| -59% | -$2.33M | ﹤0.01% | 7412 |
|
|
2021
Q1 | $4.09M | Sell |
140,875
-74,829
| -35% | -$2.27M | ﹤0.01% | 4714 |
|
|
2020
Q4 | $5.57M | Buy |
215,704
+175,013
| +430% | +$4.87M | ﹤0.01% | 3514 |
|
|
2020
Q3 | $1.25M | Sell |
40,691
-16,924
| -29% | -$591K | ﹤0.01% | 5620 |
|
|
2020
Q2 | $1.44M | Buy |
+57,615
| New | +$1.32M | ﹤0.01% | 5157 |
|
|
2020
Q1 | – | Sell |
-20,702
| Closed | -$444K | – | 9537 |
|
|
2019
Q4 | $459K | Sell |
20,702
-2,517
| -11% | -$52.1K | ﹤0.01% | 6955 |
|
|
2019
Q3 | $528K | Buy |
+23,219
| New | +$540K | ﹤0.01% | 6644 |
|
Other funds holding AKRO
Citadel Advisors's AKRO Position: Q4 2025 in Review
Citadel Advisors sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 685,842 shares — an estimated $32.6M sold.
Citadel Advisors first reported a position in AKRO in Q3 2019 and held it in 24 quarters. The position peaked at $77.3M in Q1 2025. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.
- Citadel Advisors reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
- Citadel Advisors sold 685,842 Akero Therapeutics shares in Q4 2025, an estimated $32.6M.
- Citadel Advisors first reported a position in Akero Therapeutics in Q3 2019 and held it in 24 quarters.
- Citadel Advisors's Akero Therapeutics position peaked at $77.3M in Q1 2025.
- 2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.
Based on Citadel Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.